BioNTech Announces Huge Earnings for the Last 3 Months

With a total revenue of 19 billion euros in 2021, BioNTech, shared the first quarter data of the year covering the period January – March 2022 today. The company showed its highest revenue and profit to date in the quarter. According to the shared information, the company will make a total profit in the first three months of 2022. 6 billion 374 million euro revenue achieved. This number was 2 billion 48 million euros in the same period of 2021.

BioNTech, which destroyed the expectations of a revenue of 4 billion dollars with the announcement, if it’s your net profit 3.7 billion euros announced that. This number was 1.12 billion euros in the same period of the previous year. Of course, the reason for the huge increase in BioNTech’s revenue was the revenue from the vaccine.

750 million doses of vaccine sold in the last 3 months:

While efforts are being made to gain herd immunity with vaccines all over the world, BioNTech has increased its revenue estimate from COVID-19 vaccines to 13 billion euros in 2022. increased to 17 billion euros. The company said it signed agreements with Pfizer, its partner in vaccine production, to distribute 2.4 billion doses this year to more than 100 countries and by the end of the first quarter. Billed 750 million doses of vaccine stated.

In addition to its financial situation, BioNTech is looking forward to its efforts to develop a vaccine for the Omicron variant in the coming weeks. laboratory data will be obtained announced. Working with Pfizer on a vaccine that protects against the Omicron variant, the company started a trial in January.